Small RNAs (sRNAs) are important regulatory molecules, and there are three main sRNA lessons in plants: microRNAs (miRNAs), phased small interfering RNAs (phased siRNAs or phasiRNAs), and heterochromatic siRNAs (hc-siRNAs). Excluding miRNAs, the opposite two lessons should not properly annotated or out there in public databases for many sequenced plant genomes. We carried out a complete sRNA annotation of 143 plant species which have absolutely sequenced genomes and next-generation sequencing sRNA knowledge publicly out there.
The outcomes can be found by way of an internet repository known as sRNAanno ( www.plantsRNAs.org ). Compared with different public plant sRNA databases, we obtained was rather more miRNA annotations, that are extra full and dependable as a result of of the constant and extremely stringent standards used in our miRNA annotations. sRNAanno additionally supplies free entry to genomic data for >22,721 PHAS loci and >22 million hc-siRNA loci annotated from these 143 plant species. Both miRNA and PHAS loci may be simply browsed to view their foremost options, and a group of archetypal trans-acting siRNA 3 (TAS3) genes had been annotated individually for fast entry.
To facilitate the benefit of sRNA annotation, sRNAanno supplies free service for sRNA annotations to the group. In abstract, the sRNAanno database is a superb useful resource to facilitate genomic and genetic analysis on plant small RNAs.Decompression illness (DCS) stays a significant operational concern for diving operations, submarine escape and high-altitude jumps. Aside from DCS signs, venous fuel emboli (VGE) detected with ultrasound post-dive are sometimes used as a marker of decompression stress in people, with a specificity of 100% regardless that the sensitivity is poor [1]. Being non-invasive, moveable and non-ionizing, ultrasound is especially suited to common and repeated monitoring. It might assist elucidate inter- and intra-subject variability in VGE and DCS susceptibility, however analyzing these recordings stays a cumbersome process [2].
Testing repository security evaluation fashions for deep geological disposal utilizing legacy contaminated websites
An necessary property of areas chosen to host deep geological repositories for increased stage radioactive wastes is their capability to retard the motion of any radionuclides launched from engineered limitations. Site characterization can’t measure this attribute immediately and therefore fashions kind the important hyperlink between subject observations and supporting laboratory rock/water/radionuclide interplay research. However, residual uncertainties all the time stay, related to the complexity of radionuclide interactions in pure environments and the extrapolations in time and area which can be included in security assessments. An under-used useful resource that might assist to strengthen the security instances that make the most of such data, is the data base out there from anthropogenically contaminated websites.
These have the potential to mix related geological settings with the radionuclides of curiosity and timescales in the order of many years enable usually gradual processes to be higher quantified. This paper supplies an summary of the vary of choices out there, critically critiques some related examples the place radionuclide migration fashions might be examined and descriptions work that might facilitate utilization of this potential useful resource in order to strengthen the security case for geological repositories.
Repository corticotropin injection (RCI), a posh combination of adrenocorticotropic hormone (ACTH) analogs and different pituitary peptides, has been discovered to suppress key points of gene expression and mobile operate in human B lymphocytes in vitro. The current research reveal that neither particular person POMC peptides nor different associated pituitary neuropeptides are ample to elicit these results, regardless that particular receptors succesful of transmitting indicators from these peptides are expressed by human B cells. RCI’s direct results on human B cells could require complementary indicators from a number of elements of the preparation.
Medicine Shortages: From Assumption to Evidence to Action – A Proposal for Using the FMD Data Repositories for Shortages Monitoring
Medicine shortages could negatively affect affected person care and the affected person expertise. Shortages needs to be a precedence of trade, provide chain stakeholders and nationwide competent authorities, and deserve greater than empathy or “lip-service” however critical engagement and motion. Under the overarching precept that with out right measurements in place there can’t be any enchancment in general efficiency (1), stakeholders in the pharmaceutical provide chain, notably pharmaceutical producers have made the decision for all related sources of data for use in order to offer further intelligence concerning the root causes and drivers of shortages, together with the identification of bottlenecks in the availability chain.
This paper outlines a proposal for utilizing the info saved in the interoperable community of nationwide repositories being arrange in the context of the Falsified Medicines Directive (Directive 2011/62/EU) and its Delegated Regulation 2016/161/EU on security options for offering further intelligence in monitoring shortages. The paper analyses the potential feasibility and readiness of utilizing this knowledge for monitoring shortages in addition to the strengths and weaknesses of the strategy. We discover additionally what are some of the opposite complementary knowledge sources that might be analyzed in conjunction with the info in the repository system to sharpen the general evaluation.
pHrdSV40- scFv- GCN4- sfGFP- VP64- GB1- NLS |
|||
PVT10950 | Lifescience Market | 2 ug | EUR 361.2 |
Anti-TNFRSF8 (clone Ki4) scFv-MAP ADC |
|||
ADC-W-354 | Creative Biolabs | 1mg | Ask for price |
Description: This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (clone Ki4) conjugated via a linker to a MAP |
Recombinant (E.Coli) Anti-Tetanus Toxoid scFv IgG |
|||
RP-343 | Alpha Diagnostics | 10 ug | EUR 343.2 |
Anti-ROR1 (clone R11) scFv-Fc-Sec ADC |
|||
ADC-W-434 | Creative Biolabs | 1mg | Ask for price |
Description: This ADC product is comprised of an anti-ROR1 scFv-Fc (clone R11) conjugated via a engineered selenocysteine (Sec) residue linker to a drug |
Anti-COVID-19 Nucleocapsid Protein scFv Antibody |
|||
E38A9964 | EnoGene | 100ug/100ul | EUR 225 |
Description: Available in various conjugation types. |
Biotinylated FMC63 scFv, Fc,Avitag™ (MALS verified) |
|||
CD9-BV4324b | ACROBIOSYSTEMS | 25ug | EUR 1294.7 |
Description: Biotinylated FMC63 scFv, Fc, Avitag is a chimeric monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. |
E.coli anti-COVID-19 Nucleocapsid Protein scFv Antibody |
|||
DL99719A-100ul | DL Develop | 100 ul | EUR 299 |
Description: Nucleoprotein; Nucleocapsid protein; NC; Protein N |
E.coli anti-COVID-19 Nucleocapsid Protein scFv Antibody |
|||
DL99719A-50ul | DL Develop | 50 ul | EUR 210 |
Description: Nucleoprotein; Nucleocapsid protein; NC; Protein N |
Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) |
|||
78600 | BPS Bioscience | 50 µl | EUR 1150 |
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge, 4-1BB, and CD3ζ signaling domains. |
Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv) |
|||
BSFV-072-100ug | Creative Biolabs | 100μg | EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy. |
Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv) |
|||
BSFV-072-50ug | Creative Biolabs | 50μg | EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy. |
Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv) |
|||
BSFV-162-100ug | Creative Biolabs | 100μg | EUR 4552.8 |
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy. |
Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv) |
|||
BSFV-162-50ug | Creative Biolabs | 50μg | EUR 2587.2 |
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy. |
Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-c001-100ug | Creative Biolabs | 100μg | EUR 4552.8 |
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy. |
Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-c001-50ug | Creative Biolabs | 50μg | EUR 2587.2 |
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy. |
Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-020-100ug | Creative Biolabs | 100μg | EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy. |
Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-020-50ug | Creative Biolabs | 50μg | EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy. |
Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-030-100ug | Creative Biolabs | 100μg | EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-030-50ug | Creative Biolabs | 50μg | EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-041-100ug | Creative Biolabs | 100μg | EUR 4552.8 |
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy. |
Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-041-50ug | Creative Biolabs | 50μg | EUR 2587.2 |
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy. |
Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv) |
|||
BSFV-046-100ug | Creative Biolabs | 100μg | EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv) |
|||
BSFV-046-50ug | Creative Biolabs | 50μg | EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-066-100ug | Creative Biolabs | 100μg | EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy. |
Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-066-50ug | Creative Biolabs | 50μg | EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy. |
Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-077-100ug | Creative Biolabs | 100μg | EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-077-50ug | Creative Biolabs | 50μg | EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-079-100ug | Creative Biolabs | 100μg | EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy. |
Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|||
BSFV-079-50ug | Creative Biolabs | 50μg | EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy. |
Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv) |
|||
BSFV-102-100ug | Creative Biolabs | 100μg | EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy. |
Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv) |
|||
BSFV-102-50ug | Creative Biolabs | 50μg | EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy. |
Anti-Amyloid Beta Reference Antibody (CSIRO anti-amyloid Beta scFv) |
|||
E24CHA691 | EnoGene | 100 μg | EUR 225 |
Description: Available in various conjugation types. |
Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3ζ) |
|||
78608 | BPS Bioscience | 50 µl | EUR 1095 |
Description: The anti-CD22 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (below). |
Anti-BCMA CAR Lentivirus (Clone C11D5.3 ScFv-CD8-4-1BB-CD3ζ) |
|||
78655 | BPS Bioscience | 50 µl | EUR 1095 |
Description: The anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-BCMA (clone C11D5.3) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). The lentiviruses also transduce a puromycin selection gene. |
GC Control |
|||
A23 | DataApex | - | EUR 600 |
Description: SW module for GC control |
LC Control |
|||
A24 | DataApex | - | EUR 600 |
Description: SW module for HPLC/CE control (pump, det, etc.) |
AS Control |
|||
A26 | DataApex | - | EUR 330 |
Description: SW module for AS control |
Rat Control |
|||
DEV99RC | Demeditec Diagnostics | 2 x 1 ml | EUR 60 |
Rat neurofascin (Nfasc)-control Control/blocking peptide |
|||
AB-23249-CP | Alpha Diagnostics | 100ug | EUR 196.8 |
Anti-CD20 CAR Lentivirus (Clone Leu-16 ScFv-CD8-4-1BB-CD3ζ) |
|||
78606 | BPS Bioscience | 50 µl | EUR 1095 |
Description: The anti-CD20 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD20 (clone Leu-16) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains . |
Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector) |
|||
78601 | BPS Bioscience | 50 µl | EUR 1150 |
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, 4-1BB and CD3ζ signaling domains .Note: This product transduces the same construct as the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) (BPS Bioscience #78600), but differs in key aspects:78601 is constructed with a SIN lentivector while 78600 is not. 78601 does not contain an antibiotic for selection while 78600 contains a puromycin selection so the transduced cells can be selected with puromycin. |
pMD18- Control |
|||
PVT10563 | Lifescience Market | 2 ug | EUR 319.2 |
pMD19- Control |
|||
PVT10564 | Lifescience Market | 2 ug | EUR 319.2 |
Rat IgG-PE conjugate (isotype control) (Isotype control) |
|||
20005-PE | Alpha Diagnostics | 25 tests | EUR 242.4 |
Dengue Control |
|||
ant-543 | ProSpec Tany | 100µg | EUR 165 |
Description: Mouse Anti-Dengue Control for Lateral Flow Test |
Control Slides |
|||
24012-1 | Polysciences Europe GmbH | 1box | EUR 78 |
Canine Control |
|||
DEV99CC | Demeditec Diagnostics | 2 x 1 ml | EUR 60 |
Rat IgG-HRP conjugate (isotype control) (Isotype control) |
|||
20005-HP | Alpha Diagnostics | 100 ug | EUR 196.8 |
Rat IgG-FITC conjugate (isotype control) (Isotype control) |
|||
20005-F | Alpha Diagnostics | 100 ug | EUR 196.8 |
Quality Control |
|||
abx098966-1vial | Abbexa | 1 vial | EUR 360 |
Rat IgG-Biotin conjugate (isotype control) (Isotype control) |
|||
20005-B | Alpha Diagnostics | 100 ug | EUR 196.8 |
PIPET CONTROLLER CONTROL BOARD |
|||
357484 | CORNING | 1/pk | EUR 104.4 |
Description: Falcon Liquid Handling Equipment; Falcon Pipet Controllers and Accessories |
Goat IgG (-ve control for flow cytometry) (isotype control) |
|||
20011-100 | Alpha Diagnostics | 100 test | EUR 123.6 |
Control siRNA Vector (pGB-control) |
|||
9500C-20 | Biovision | each | EUR 405.6 |
OOSA10387-100T - IgM NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10387-100T | Aviva Systems Biology | 100Tests | EUR 309 |
OOSA10342-100UG - IgG1 NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10342-100UG | Aviva Systems Biology | 0.1mg | EUR 219 |
OOSA10349-100T - IgG2a NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10349-100T | Aviva Systems Biology | 100Tests | EUR 299 |
OOSA10380-100T - IgG2b NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10380-100T | Aviva Systems Biology | 100Tests | EUR 309 |
OOSA10389-100T - IgG1 NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10389-100T | Aviva Systems Biology | 100Tests | EUR 309 |
OOSA10397-100T - IgG2a NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10397-100T | Aviva Systems Biology | 100Tests | EUR 309 |
EUROSTAR 200 control Overhead Stirrer with wireless control unit |
|||
STI2876 | Scientific Laboratory Supplies | EACH | EUR 5433.6 |
EUROSTAR 100 control Overhead Stirrer with wireless control unit |
|||
STI2878 | Scientific Laboratory Supplies | EACH | EUR 3648 |
Rat Control IgG |
|||
AC034 | Abclonal | 100 ul | EUR 159.6 |
β-Gal Control |
|||
LV007 | ABM | 4 x 500 ul | EUR 195 |
NF-κB Control |
|||
T37559-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: NF-κB Control |
NF-κB Control |
|||
T37559-1g | TargetMol Chemicals | 1g | Ask for price |
Description: NF-κB Control |
NF-κB Control |
|||
T37559-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: NF-κB Control |
NF-κB Control |
|||
T37559-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: NF-κB Control |
NF-κB Control |
|||
T37559-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: NF-κB Control |
EDG-1 Control |
|||
BC-009 | Kamiya Biomedical Company | 100 uL | EUR 350 |
EDG-2 Control |
|||
BC-011 | Kamiya Biomedical Company | 100 uL | EUR 350 |
EDG-4 Control |
|||
BC-012 | Kamiya Biomedical Company | 100 uL | EUR 350 |
EDG-6 Control |
|||
BC-014 | Kamiya Biomedical Company | 100 uL | EUR 350 |
EDG-7 Control |
|||
BC-016 | Kamiya Biomedical Company | 100 uL | EUR 350 |
EUROSTAR 60 control Overhead Stirrer with wireless control unit |
|||
STI2886 | Scientific Laboratory Supplies | EACH | EUR 2894.4 |
Goat IgG control |
|||
31R-AG001 | Fitzgerald | 1 mg | EUR 152.4 |
Description: Goat Immunoglobulins Goat IgG control |
Goat IgG Control |
|||
GT15900 | Neuromics | 1 mg | EUR 199.2 |
MG-BSA Control |
|||
STA-306 | Cell Biolabs | 100 µg | EUR 386.4 |
Description:
|
Mouse IgG Control |
|||
10R-I169A | Fitzgerald | 250 ug | EUR 152.4 |
Description: Mouse Immunoglobulins Mouse IgG Control |
Mouse Control IgG |
|||
AC011 | Abclonal | 100 ul | EUR 159.6 |
Mouse IgM Control |
|||
ICIGMF-100 | ImmunoStep | 100 µg | EUR 239.4 |
Mouse IgM Control |
|||
ICIGMPU-100 | ImmunoStep | 100 µg | EUR 239.4 |
CEL-BSA Control |
|||
STA-302 | Cell Biolabs | 100 µg | EUR 386.4 |
Description:
|
CML-BSA Control |
|||
STA-314 | Cell Biolabs | 100 µg | EUR 386.4 |
Description:
|
MDA-BSA Control |
|||
STA-333 | Cell Biolabs | 100 µg | EUR 386.4 |
Description:
|
HNE-BSA Control |
|||
STA-335 | Cell Biolabs | 100 µg | EUR 386.4 |
Description:
|
human IgM control |
|||
E4A11C04 | EnoGene | 50ug | EUR 255 |
Description: Available in various conjugation types. |
human IgE control |
|||
E4A11C05 | EnoGene | 50ug | EUR 255 |
Description: Available in various conjugation types. |
Vacuum Controller w Control Unit |
|||
PUM3016 | Scientific Laboratory Supplies | EACH | EUR 2559.6 |
OOSA10361-1ML - Rat IgG2a NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10361-1ML | Aviva Systems Biology | 1ml | EUR 169 |
Rabbit Control IgG |
|||
AC005 | Abclonal | 100 ul | EUR 159.6 |
Rabbit IgG Control |
|||
31R-AR001 | Fitzgerald | 500 ug | EUR 159.6 |
Description: Purified Normal Rabbit IgG |
Human IgG1 Control |
|||
HY-P9900 | MedChemExpress | 5mg | EUR 776.4 |
Mouse IgG1 Control |
|||
ICIGG1A-50 | ImmunoStep | 50 µg | EUR 387.6 |
Mouse IgG1 Control |
|||
ICIGG1AC750-50 | ImmunoStep | 50 µg | EUR 855.6 |
Mouse IgG1 Control |
|||
ICIGG1CFB-100 | ImmunoStep | 100 µg | EUR 387.6 |
Mouse IgG1 Control |
|||
ICIGG1F-100 | ImmunoStep | 100 µg | EUR 239.4 |
Mouse IgG1 Control |
|||
ICIGG1PE-50 | ImmunoStep | 50 µg | EUR 387.6 |
Mouse IgG1 Control |
|||
ICIGG1PP-100 | ImmunoStep | 100 µg | EUR 387.6 |
Mouse IgG1 Control |
|||
ICIGG1PP5.5-100 | ImmunoStep | 100 µg | EUR 387.6 |
Mouse IgG1 Control |
|||
ICIGG1PU-100 | ImmunoStep | 100 µg | EUR 239.4 |
Mouse IgG3 Control |
|||
ICIGG3A-50 | ImmunoStep | 100 µg | EUR 777.6 |
Mouse IgG3 Control |
|||
ICIGG3CFB-100 | ImmunoStep | 100 µg | EUR 465.6 |
Mouse IgG3 Control |
|||
ICIGG3F-100 | ImmunoStep | 100 µg | EUR 387.6 |
Mouse IgG3 Control |
|||
ICIGG3PE-50 | ImmunoStep | 50 µg | EUR 621.6 |
Mouse IgG3 Control |
|||
ICIGG3PU-100 | ImmunoStep | 100 µg | EUR 387.6 |
VACUUM CONTROL KIT |
|||
ZAFSVCKIT | Scientific Laboratory Supplies | EACH | EUR 381.24 |
human IgG1 control |
|||
E4A11C03 | EnoGene | 50ug | EUR 255 |
Description: Available in various conjugation types. |
PAS Control Slides |
|||
HCS1016-25 | ScyTek Laboratories | 25 Slides | EUR 137.81 |
CD3 Control Slides |
|||
ICS2005-25 | ScyTek Laboratories | 25 Slides | EUR 137.81 |
CD5 Control Slides |
|||
ICS2006-25 | ScyTek Laboratories | 25 Slides | EUR 137.81 |
CD8 Control Slides |
|||
ICS2007-25 | ScyTek Laboratories | 25 Slides | EUR 137.81 |
CEA Control Slides |
|||
ICS2012-25 | ScyTek Laboratories | 25 Slides | EUR 137.81 |
EMA Control Slides |
|||
ICS2018-25 | ScyTek Laboratories | 25 Slides | EUR 137.81 |
LCA Control Slides |
|||
ICS2029-25 | ScyTek Laboratories | 25 Slides | EUR 137.81 |
NSE Control Slides |
|||
ICS2031-25 | ScyTek Laboratories | 25 Slides | EUR 137.81 |
PSA Control Slides |
|||
ICS2033-25 | ScyTek Laboratories | 25 Slides | EUR 137.81 |
Human IgG1 Control |
|||
TP1357-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: Human IgG1 Control |
Human IgG1 Control |
|||
TP1357-1g | TargetMol Chemicals | 1g | Ask for price |
Description: Human IgG1 Control |
Human IgG1 Control |
|||
TP1357-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: Human IgG1 Control |
Human IgG1 Control |
|||
TP1357-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: Human IgG1 Control |
Human IgG1 Control |
|||
TP1357-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: Human IgG1 Control |
OOSA10379-250UG - Rat IgG2c NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10379-250UG | Aviva Systems Biology | 0.25mg | EUR 319 |
EUROSTAR 200 control P4 Overhead Stirrer with wireless control unit |
|||
STI2882 | Scientific Laboratory Supplies | EACH | EUR 7819.2 |
Lastly, we offer a theoretical however concrete use case for utilizing the abovementioned knowledge for higher informing choices to forestall and mitigate shortages. In doing so, we clarify the interlink between affected person wants at nation stage, demand from financial actors, intra-EU parallel commerce and manufacturer-imposed provide quotas and suggest a mechanism for collaboration between nationwide competent authorities and provide chain stakeholders for early detection and motion to forestall drugs shortages from occurring.